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Innate immune mechanisms that follow early recognition of microbes influence the nature
and magnitude of subsequent adaptive immune responses. Early detection of microbes
depends on pattern recognition receptors that sense pathogen-associated molecular pat-
terns or microbial-associated molecular patterns (PAMPS or MAMPs, respectively). The
bacterial envelope contains MAMPs that include membrane proteins, lipopeptides, gly-
copolymers, and other pro-inflammatory molecules. Bacteria are selected by environmental
pressures resulting in quantitative or qualitative changes in their envelope structures that
often promote evasion of host immune responses and therefore, infection. However, recent
studies have shown that slight, adaptive changes in MAMPs on the bacterial cell wall may
result in their ability to induce the secretion not only of pro-inflammatory cytokines but
also of anti-inflammatory cytokines. This effect can fine-tune the subsequent response to
microbes expressing these MAMPs and lead to the establishment of a commensal state
within the host rather than infectious disease. In this review, we will examine the plasticity
of Toll-like receptor (TLR) 2 signaling as evidence of evolving MAMPs, using the better-
characterized TLR4 as a template. We will review the role of differential dimerization of
TLR2 and the arrangement of signaling complexes and co-receptors in determining the
capacity of the host to recognize an array of TLR2 ligands and generate different immune
responses to these ligands. Last, we will assess briefly how this plasticity may expand
the array of interactions between microbes and immune systems beyond the traditional
disease-causing paradigm.
Keywords: toll-like receptors, gram-positive bacteria, commensal bacteria, microbiota, immune response
INTRODUCTION
Innate immunity is characterized by an immediate response
against pathogens and is paramount in the initial control of infec-
tion. Toll-like receptors (TLRs) are thought to be among the most
ancient pathogen recognition systems (1). Such systems recognize
pathogen- or microbial-associated molecular patterns (PAMPs or
MAMPs) that are relatively conserved among microorganisms
but are absent in hosts. This recognition involves pattern recog-
nition receptors (PRRs) that are broadly expressed by a variety
of immune cells such as monocytes, macrophages, dendritic cells
(DCs), and some epithelial cells. PRR-dependent responses are
critical for promoting inflammatory processes leading to microbial
clearance.
The genes encoding receptors of the innate immune system
are inherited and not subject to gene rearrangement like those
coding for adaptive immune receptors. As a result, the innate
response has been traditionally considered fairly static in its
recognition of microbial patterns, and to be largely indiscrimi-
nate in promoting inflammation and priming adaptive immunity.
However, emerging evidence indicates that PRR signaling can
also promote anti-inflammatory responses under certain condi-
tions (2–5). The precise role of PRR-induced anti-inflammatory
responses in the context of innate immunity remains uncertain.
Recent evidence suggests that these anti-inflammatory responses
may play an important role in the regulation of the homeosta-
tic tolerance to commensal organisms or uncontrolled microbial
proliferation (6).
Two views of the biology of PRR-induced responses may be
considered. One is that host responses to MAMPs vary depending
on the context of exposure (e.g., site, responding cell type, expres-
sion of co-receptors by responding cell, etc.), which ultimately
determines the type of response (pro- vs. anti-inflammatory
responses). Alternatively, we should not forget that MAMPs are
subject to evolutionary modification as a result of selective pres-
sures by host defense mechanisms, and that this evolution will
ultimately expand the array of ligands to a given PRR and
the signals that it can deliver. However, co-evolution of both
MAMPs as well as host responses can explain the two oppo-
site outcomes of PRR signaling. In this review, we will focus
only on TLRs, and specifically on TLR2 and TLR4, to review
the plasticity of signaling by these receptors and its biological
implications.
OVERVIEW OF TOLL-LIKE RECEPTORS
Toll-like receptors were the first class of PRRs identified. In
1989, Charles Janeway hypothesized that the innate immune
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system senses the presence of microbes by recognizing commonly
associated molecular signatures (7). In 1996, his hypothesis was
vindicated with the discovery of the Toll pathway in Drosophila and
its role in controlling fungal infections (8) and subsequently with
the characterization of associated PRRs Gram-negative bacteria
binding protein 3 (GNBP3) and peptidoglycan (PGN) recogni-
tion protein SA (PGRP-SA), which recognize bacterial and fungal
MAMPs (9, 10). Soon after, Medzhitov et al. (11) discovered a
human homolog for Toll, at the time termed hToll, which was
found to activate the transcription factor NF-κB. Mice deficient in
this receptor were unable to induce pro-inflammatory cytokines
to lipopolysaccharide (LPS) (12). This receptor, later called TLR4,
was the first member of the TLR family of receptors to be charac-
terized, a family that now includes 13 members, 10 of which are
expressed in humans (13).
Structural studies have characterized TLRs as type I transmem-
brane proteins with leucine-rich repeats (LRRs) on the extra-
cellular N-terminal domain (13). This LRR domain contains an
α-helix and a β-strand linked by loops, leading to the prediction
that the ectodomain of TLRs assume a horseshoe conformation
(14). The intracellular C-terminal portion of TLRs contains a
Toll/interleukin-1 receptor (TIR) domain, which is common to
all members of the TLR family (15).
Toll-like receptors are constitutively expressed on monocytes,
macrophages, and DCs, while certain TLRs are also expressed on
other cell types such as neutrophils, mast cells, epithelial cells,
and B cells (13). TLR1, 2, 4, 5, 6, and 10 are expressed on the cell
surface, while TLR 3, 7, 8, and 9 are expressed in intracellular com-
partments such as the endosome, lysosome, and the endoplasmic
reticulum (1). TLRs 1–9 are conserved between humans and mice.
TLR10 is a non-functional pseudogene in mice due to a retroviral
insertion, but is nonetheless a functional receptor in humans (16).
TLRs 11, 12, and 13 are poorly characterized and are absent from
the human genome (17).
Through TLRs, the host can recognize a wide variety of micro-
bial ligands including nucleic acids, lipids, lipoproteins, and poly-
saccharides. TLRs can be grouped according to their recognition
of similar MAMPs. For example, TLRs 3, 7, 8, 9, and 13 all recog-
nize nucleic acids. However, TLRs can also recognize a repertoire
of structurally unrelated ligands. TLR4 has long been recognized
as the receptor for LPS, but also recognizes heat-shock proteins
(18), glycoproteins such as fibronectin (19), the fusion protein
of respiratory syncytial virus (RSV) (20), and the plant diter-
pene and chemotherapy drug paclitaxel (21, 22). Similarly, TLR2
can recognize lipoteichoic acid (LTA), PGN, lipopeptides, and
zymosan (reviewed in Ref. (13) and see below). Unlike TLR4 which
signals as a homodimer, TLR2 forms heterodimers with TLR1,
TLR6, and perhaps TLR10, hinting at a potential mechanism
to discriminate microbial ligands and elicit varied downstream
responses.
Toll-like receptors function as important immune receptors
that, in coordination with other PRRs, turn on innate mechanisms
of immunity, including inflammation. It is thus expected that
changes in TLR ligand binding and signaling capacity will translate
in changes in innate immunity. This is well illustrated by obser-
vations that certain polymorphisms in TLRs have been associated
with increased susceptibility to a myriad of infectious diseases (23,
24) and to some non-infectious diseases such as cancer (25–27).
MOLECULAR BASIS OF TLR2 AND TLR4 SIGNALING
Since the discovery of TLRs, signaling from these receptors has
been recognized as potently eliciting pro-inflammatory responses
in the host (15). The bacterial endotoxin LPS found in the Gram-
negative bacterial cell wall, and lipopeptides and glycopolymers
in the PGN layer of Gram-positive bacterial cell wall are potent
stimulants of inflammation, following TLR4 and TLR2 recogni-
tion respectively. PGN can stimulate inflammation via other PRRs
such as nucleotide-binding oligomerization domain-containing
protein (NOD1) and NOD2. Inflammation is characterized by the
production of a vast array of cytokines including IL-1β, IL-6, and
TNFα, as well as chemokines such as IL-8 and MCP-1/CCL-2,
and type I interferons (IFN) through the NF-κB and IRF3 tran-
scription factors. The observation that down-regulation of TLR2-
mediated signaling with transmembrane domain-derived peptides
reduces lethality in mice following intraperitoneal challenge with
Staphylococcus aureus (28) illustrates that these pro-inflammatory
mediators may be deleterious to the host when left unchecked.
Signaling from TLR2 and TLR4 is initiated by their ligand-
induced dimerization. This step brings the TIR domains in their
cytoplasmic tails into close proximity, forming a platform for sig-
naling through TIR domain-containing adaptor molecules. TLR2
and TLR4 are phosphorylated on tyrosine residues, and deficien-
cies in their phosphorylation are associated with defective dimer-
ization and impaired recruitment of TIR domain-containing
adaptors (29, 30). Five TIR domain-containing adaptors have
been identified: MyD88, MAL/TIRAP, TRIF, TRAM, and SARM
[reviewed in Ref. (31)]. MyD88 was the first such adaptor dis-
covered, and is involved in the signaling of all the TLRs except
TLR3. TLR4 is known to utilize two distinct signaling pathways
(MyD88-dependent and MyD88-independent pathways), medi-
ated by different TIR domain-containing adaptor molecules, and
leading to the induction of pro-inflammatory cytokines through
mitogen-activated protein (MAP) kinase and NF-κB activation.
However, MyD88-deficient mice challenged with LPS were still
able to induce the activation of NF-κB and JNK (a MAP kinase)
with a delayed response (32). This MyD88-independent, TRIF-
dependent pathway was later shown to induce pro-inflammatory
cytokines as well as type I IFN through IRF3 (33). TRIF was found
to interact with both TLR3 and TLR4, but TRIF-deficient mice
did not produce type I IFN in response to TLR3 or TLR4 ligands
(34, 35). In contrast to TLR4, TLR2 mostly depends on the adap-
tors MyD88 and TIRAP/MAL for signaling (36, 37). Mice deficient
in MAL displayed a similar phenotype to MyD88 knockout mice
when challenged with LPS, exhibiting delayed activation of NF-κB
and MAPKs (37). MAL is thought to be particularly important for
TLR2 signaling, as activation of NF-κB and MAPKs is impaired
to a greater extent in MAL-deficient cells following PGN stim-
ulation compared to LPS stimulation (36). Additional roles for
cell-type-specific TLR2 adaptors have been reported. For exam-
ple, peritoneal but not bone-marrow-derived macrophages can
produce IFN-β through IRF3 and IRF7 in manner independent of
MAL but dependent on TLR2 and TRIF (38).
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DIFFERENTIAL SIGNALING BY GRAM-NEGATIVE BACTERIA:
AN INDICATION FOR EVOLVING INNATE IMMUNE
RECOGNITION
Lipopolysaccharide is the major component of the outer leaflet of
the Gram-negative cell envelope (12, 39, 40) and as such is the most
abundant Gram-negative MAMP capable of inducing an immune
response. LPS is composed of an O-antigen polysaccharide chain,
an oligosaccharide core, and a lipid A anchor (41). The O-antigen
polysaccharide projects away from the bacterial cell and its struc-
ture is highly variable from strain to strain. The oligosaccharide
core component serves as a linker between the O-antigen and the
lipid A anchor, which is the primary mediator of LPS toxicity
through TLR4-mediated recognition and signaling, causing fever,
diarrhea, and septic shock (42).
Lipid A, however, is not absolutely conserved across species.
Hexa-acylated forms of lipid A found in Escherichia coli and Sal-
monella enterica serovar Typhimurium are potent activators of
TLR4 (43, 44). This pro-inflammatory response is demonstrated
by the production of IL-1β, IL-6, IL-12p40, and TNFα by mono-
cytes and DCs leading to the organization of an inflammatory
response at the site of infection (42). Conversely, tetra-acylated
forms found in Helicobacter pylori and some forms of Pseudomonas
aeruginosa do not activate TLR4 to a similar extent (45–47). Addi-
tionally, LPS species from Porphyromonas gingivalis induce TNFα
and IL-1 but not IL-12 and IFN-γ via a TLR2-mediated mecha-
nism, and LPS from Rhodobacter sphaeroides does not induce pro-
inflammatory cytokine production (48). These species- and/or
strain-specific differences point to diversity in TLR4 ligands as well
as the versatility of innate immune receptors in cross-recognition
of diverse MAMPs. Such diversity and versatility is consistent with
the evolving nature of the bacterial cell wall.
In addition to differences in stimulatory capacity of LPS
between bacterial strains, some microbes alter their lipid A moi-
eties in response to environmental cues, a change that also trans-
lates into diversity in host recognition and response (49). This phe-
nomenon is well documented for the PhoP/PhoQ two-component
system in Salmonella spp. (50). PhoQ, located on the inner mem-
brane, is activated by anti-microbial peptides, low magnesium
concentrations, and/or acidic pH (51). Following activation, PhoQ
phosphorylates and activates the transcriptional regulator PhoP.
One of PhoP’s effector functions results in the modification of
lipid A by the 3-O-deacylase, PagL, and a palmitoyl transferase,
PagP. PagL modifies lipid A by removing one fatty acid chain and
creating a penta-acylated lipid A (52, 53). In contrast, PagP mod-
ifies lipid A by adding an additional fatty acid chain, creating a
hepta-acylated lipid A. When both enzymes modify a lipid A moi-
ety, the end result is a hexa-acylated lipid A with one less acyl chain
linked to the core region and an additional acyl chain linked via
another fatty acid. Kawasaki et al. (53) identified that the lipid A
products of PagL and/or PagP led to a decrease in TLR4-mediated
NF-κB activation. This PhoP/PhoQ two-component system iden-
tifies just one example of a modification in S. enterica lipid A that
modulates the innate immune response. This system is thus a good
example to illustrate the evolving nature of the bacterial cell wall.
Lipopolysaccharide has also been reported to induce the pro-
duction of the anti-inflammatory cytokine IL-10 in co-cultures
of T cells with stimulated DCs as well as in primed DCs (54).
For example, LPS from Pseudoalteromonas strains was able to
modulate the pro-inflammatory response to E. coli LPS owing
to a combination of low immunostimulatory activity as well as
competition for TLR4 (55). Co-stimulation with the two types of
LPS resulted in lower pro-inflammatory cytokine production and
higher IL-10. This indicated an additional potential role for LPS
from commensal bacteria in maintaining immune homeostasis
and preventing inflammatory diseases.
The evidence discussed above suggests that a single MAMP
from different species can take on various forms and possess dif-
ferent immunostimulatory capacity via the same PRR based on
modifications induced by environmental stimuli. Furthermore, a
potential regulatory role may be played by LPS with regards to
competition for TLR4 and induction of IL-10 in a mechanism
that has yet to be elucidated. Experimental models of inflamma-
tory bowel disease (IBD) have helped to identify genetic factors
that reveal host susceptibilities to impairment of gut immune
homeostasis (38). However, the products and components of the
microbiota, such as LPS, may play a larger role in setting the bal-
ance of organisms in a given microbiota and the maintenance of
the local immune environment (6, 56).
ANTI-INFLAMMATORY TLR4 SIGNALING
Although the pro-inflammatory effects of TLR4 signaling have
been described in detail, the anti-inflammatory responses induced
by TLR4 activation are much less characterized. The cell com-
partment where TLR4 signaling occurs seems to be an impor-
tant factor when it comes to differentiating between pro- and
anti-inflammatory signaling. Contrary to TLR4 pro-inflammatory
signaling at the cell surface, TLR4 signaling from endosomal com-
partments induces the secretion of the anti-inflammatory cytokine
IL-10 (2). This compartment-dependent effect is due to a shift
from MyD88/MAL-dependent pro-inflammatory signaling at the
cell surface to TRIF/TRAM-mediated anti-inflammatory signal-
ing in the endosome, and is mediated by the p110δ isoform of
PI3-kinase (PI3K). This PI3K isoform is involved in the TLR4
internalization, dissociation of MAL from the cell membrane, and
subsequent degradation of MAL by calpain (2). Therefore, a shift
in adaptor molecule use is associated with a shift in cytokine
expression (Figure 1): the MyD88-dependent pathway leads to
the production of inflammatory cytokines such as IL-1β, IL-6, and
TNFα, whereas the TRIF-dependent pathway induces IFN-β and
IL-10. This model is corroborated by the observation that inacti-
vation of p110δ results in higher levels of the pro-inflammatory
cytokines and lower levels of IFN-β and IL-10.
Other signaling events downstream of TLR4 activation leading
to this anti-inflammatory response are unclear. The MAP kinases
p38 and JNK have been shown to be necessary for IL-10 secre-
tion by bladder epithelial cells (BECs) (57). Inhibition of p38
and JNK in LPS-activated BECs reduces STAT3 expression, and
this enhances IL-10 secretion (58). Therefore, the balance between
pro- and anti-inflammatory TLR4 signaling may depend not only
on the use of either the MyD88/MAL or TRIF/TRAM adaptor
proteins respectively, but also on additional factors. TRIF also
plays a role in pro-inflammatory signaling, as evidenced by the
complete abrogation of LPS-stimulated NF-κB and JNK activa-
tion in MyD88 and TRIF double knockout mice (35) but not in
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FIGURE 1 | Regulation of pro- and anti-inflammatoryTLR4 signaling. In
the resting state, phosphatidylinositol on the cell surface exists mostly as
PIP2, allowing the recruitment of MAL/TIRAP which contains a PIP2 binding
domain. Following stimulation with LPS, TLR4 activation leads to the
recruitment of adaptors TIRAP/MAL and MyD88 during early stages of MAMP
recognition to promote the production of inflammatory cytokines through the
MAP kinases JNK and p38 as well as the NF-κB transcription factor. The
phosphorylation of PIP2 into PIP3 by the p110δ isoform of PI3K causes the
translocation of the receptor-ligand complex into endosomal compartments,
where TLR4 signals through the adaptors TRIF and TRAM to induce the
secretion of IL-10 and type I IFNs through MAP kinases, NF-κB, and IRF3. This
mechanistic framework is likely operational in macrophages but not in DCs
depending on expression of DC-SCRIPT, a transcription factor which
suppresses IL-10 expression.
mice deficient for MyD88 alone, although the latter have delayed
kinetics compared to wild-type control mice (32). Furthermore,
quantitative proteomic analysis of the secretome of LPS-activated
murine bone-marrow-derived macrophages suggests that both
MyD88 and TRIF are required for full IL-10 expression, since
IL-10 secretion was at least 100-fold greater when both adap-
tors were present compared to conditions in which only one was
present (59).
AN EXPANDING ARRAY OF TLR2 LIGANDS
TLR2, in conjunction with other TLRs (see below),has been identi-
fied as a receptor for an array of ligands including PGN-embedded
LTA, di- and tri-acylated lipopeptides, lipoproteins, and others
including LPS variants (60, 61), zymosan from fungi, lipoarabino-
mannan from mycobacteria, glycosylphosphatidyl inositol mucin
from Trypanosoma cruzi, hemagglutinin protein from measles
virus, and phospholipomannan from Candida albicans [reviewed
in Ref. (13)]. The envelope of Gram-positive bacteria contains a
multitude of molecules that can act as MAMPs. These include the
glycopolymers wall teichoic acid (WTA) and LTA, PGN fragments,
lipopeptides and lipoproteins, and other proteins (40).
For years, LTA has been touted as an LPS equivalent for Gram-
positive bacteria by acting through a TLR2-mediated mechanism.
LTA is a structural glycopolymer within the cell wall that is
anchored to the cell membrane but protrudes outward through
the cell wall (40). It is constituted of a polymer of repetitive
1,3-phosphodiester-linked glycerol-1-phosphate units with a gly-
colipid anchor. Some glycerol phosphate subunits are substituted
with d-alanine residues, and are responsible for the stimulating
properties of this molecule when tested with synthetic LTA (62).
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This substitution is also partially responsible for the resistance
of some Gram-positive species to anti-microbial peptides (63).
The glycolipid anchor often contains two acyl chains that may be
responsible for binding to TLR2 (62). The precise contribution of
LTA to the overall TLR2-triggered response is uncertain (64). It has
been reported that only lipoproteins and lipopeptides can induce
TLR2 signaling under physiological concentrations and that other
cell wall fractions (such as the LTA fraction) are contaminated by
these molecules (64, 65).
Although both lipoproteins and PGN are found in both Gram-
negative and Gram-positive species, the magnitude of LPS-TLR4
interaction often overshadows the immunostimulatory capacity
of lipoproteins in Gram-negative bacteria. Although lipoproteins
are likely a primary bacterial ligand for TLR2 (64), most experi-
mental data on TLR2 function has been generated using synthetic
lipopeptides. Structural studies using the synthetic lipopeptides
Pam2CSK4 and Pam3CSK4 show that TLR2 dimerized with TLR1
recognizes triacylated lipoproteins while TLR2–TLR6 dimers rec-
ognize diacylated lipoproteins (66, 67). This functional distinction
aligns with the structural conformation observed from the crys-
tal structures of these heterodimers (66). Intriguingly, the acyl
chains of the lipoproteins, which are hypothesized to bind to
TLRs, are embedded into the bacterial membrane, making it
uncertain whether they are accessible to immune receptors. In
Gram-positive bacteria, the lipoproteins are found below the PGN
wall but on the outer leaflet of the cytoplasmic membrane (40). In
Gram-negative bacteria, the lipoproteins are found on the outer
leaflets of the inner and outer membranes. However, Boneca et
al. (68) have shown that phagocytosis and proteolytic destruction
of S. aureus by macrophages may be necessary for TLR-mediated
responses and in this way contribute to the generation of ligands
for TLR2 or NOD receptors that amplify the innate response to
these bacteria. Furthermore, some triacylated lipoproteins have
been found to induce an immune response dependent on TLR2
but independent of TLR1 or TLR6 (69). Of interest, environmen-
tal conditions may impact the balance between di- vs. tri-acylated
lipopeptide expression by bacteria and, thus influence the type
of ensuing responses (70). Gram-positive bacteria can also mod-
ify their MAMPs in response to selective pressures applied by the
host immune system. Listeria monocytogenes peptidoglycan N -
deacetylase (PgdA) decreases its recognition by innate immune
receptors, playing a role in immune evasion. Strains with this gene
knocked out displayed increased sensitivity to lysozyme, impaired
survival in macrophages, and impaired virulence in vivo in BALB/c
and C57/BL6J mice (68). Based on the heterogeneity of TLR2
ligands, it is plausible to suggest that there may be an array of
ligands for TLR2 that results from environmental selection upon
microbial-host interactions. If this is the case, then fine charac-
terization of mechanisms involved in TLR2-mediated recognition
and signaling may turn out to be a much more laborious exercise
than initially thought.
PLASTICITY IN TLR2 SIGNALING
As mentioned above, the MAMPs that can act as TLR2 ligands
(in association with TLR1, TLR6, and maybe TLR10) are many
and structurally diverse, albeit sharing lipid moieties (13). The
variation in structure and biological origins suggest that there is
a considerable plasticity in TLR2-dependent recognition and sig-
naling. Indeed, like TLR4, TLR2 has recently been recognized as
capable of eliciting anti-inflammatory cytokine responses (3–5).
For example, upon stimulation with staphylococcal PGN prepa-
rations, peripheral blood mononuclear cells (PBMCs) produced
IL-10 through a TLR2-dependent mechanism, down-regulating
the T cell response to staphylococcal superantigens (69). Further
studies indicated that the PI3K-Akt pathway was indispensible
for IL-10 production, as the IL-10 response was associated with
Akt phosphorylation and was inhibited by the PI3K inhibitor
wortmannin (71).
Unlike TLR4 which signals as a homodimer, TLR2-dependent
MAMP recognition and signaling requires, under most circum-
stances, formation of TLR2 heterodimers. TLR2 is thought to exist
in pre-formed low affinity complexes associated with TLR1 and
TLR6 under basal conditions and dimerizes upon ligand bind-
ing (66), heterodimerizing with TLR1 or TLR6 upon recognition
of triacylated and diacylated lipopeptides respectively (72, 73).
Such a heterodimerization of TLR2 has been considered a factor
potentially determining the ensuing pro- vs. anti-inflammatory
responses. In general, TLR2/1 complexes have been more often
linked with pro-inflammatory responses than TLR2/6 complexes,
which have been linked with anti-inflammatory responses (4, 74).
The structural basis for this difference is unknown at the moment.
In addition, it has been claimed that TLR2 homodimers may
down-regulate TLR2-dependent responses. However, the evidence
for this claim is solely based on in vitro recombinant systems,
using chimeric proteins of the extracellular domain of CD4 fused
with the transmembrane and intracellular domains of TLR2, and
may not take into account other regulatory factors associated with
natural ligand-induced TLR2 dimerization (72).
Other cell surface PRRs that could associate with TLR2 can
also contribute to the different functional outcomes of TLR2
engagement. SitC, a triacylated lipoprotein found in S. aureus,
was recently shown to induce IL-6 and TNFα through TLR2 and
MyD88 in peritoneal macrophages (75). This was observed even
in mice deficient in TLR1 and TLR6, suggesting that TLR2 can sig-
nal through dimers other than TLR2/1 and TLR2/6, either TLR2
homodimers or, alternatively, TLR2 dimerizing with other PRRs.
In human cells, one such candidate could be TLR10. Although not
expressed in mouse cells, TLR10 is a functional MyD88-dependent
receptor in humans, being expressed on B cells and certain DC
subsets (16). In 2001, TLR10 was identified as a receptor with the
characteristic LRRs and Toll/IL-1 receptor TIR domains shared by
all TLRs (76). Importantly, this study found that TLR10 was highly
homologous to TLR1 and TLR6 with an overall amino acid iden-
tity of 50 and 49% respectively, whereas it was only 30% identical
to TLR2 and no more than 25% for the other TLRs. Phylogenetic
studies on TLR evolution indicate that TLR10 predates TLR1 and
TLR6, suggesting that TLR1 and TLR6 arose from gene duplica-
tion, consistent with the observation that TLR10, TLR1, and TLR6
lie in tandem on human chromosome 4 (77). It has been sug-
gested that TLR10 shares ligand recognition with TLR1 but signals
differently (78). Given that TLR10 polymorphisms have been asso-
ciated with various human pathologies (79–81), TLR10 represents
a promising direction in which to increase our understanding of
the plasticity of TLR2 responses.
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Another factor to consider in the signaling properties of TLR2
is the availability of co-receptor molecules. Among these, CD14
(82) and CD36 (83) are accessory molecules known to contribute
to certain responses to TLR2 signaling [reviewed in Ref. (84)].
Availability of these molecules is important for pro-inflammatory
responses to TLR2 ligation but not for IL-10 production (71).
These accessory proteins are known to bind to TLR ligands. CD14,
for example, is able to bind LPS, PGN (85, 86), Pam3CSK4 (87),
polyI:C (88), and CpG DNA (89). They also play a role in lig-
and discrimination, as loss of CD36 impairs the TNFα response
against LTA and the TLR2/6 ligand MALP2, but not Pam2CSK4,
Pam4CSK4, LPS, PGN, zymosan, polyI:C, or CpG DNA (90). MD2
has also been shown to associate with both TLR4 and TLR2 to
enhance signaling by their cognate ligands (91). It is unknown
whether binding of these accessory proteins changes the confor-
mation of the intracellular domains of TLRs and, if so, how this
affects signaling. The use of peptides mimicking the intracellu-
lar domains of TLRs offers a promising platform to study TLR
dimerization and receptor assembly (28).
Although PI3K has been shown to regulate the balance of pro-
vs. anti-inflammatory responses following TLR4 activation, the
precise regulatory role of PI3K in the regulation of pro- vs. anti-
inflammatory signaling from other TLRs, and specifically from
TLR2, remains untested. While PI3K-dependent regulation of
TLR4 anti-inflammatory signaling has been shown to involve dif-
ferential compartmentalization of the TLR complex, TLR2 only
induces TNFα and type I IFN from endosomal compartments (56,
92). Like TLR4, TLR2 also uses the MAL adaptor molecule, and
activation of TLR2/6 with diacylated lipopeptides has been shown
to lead to MAL-p85α interaction and Akt-mediated macrophage
polarization, suggesting a potential mechanism for TLR2 signal-
ing plasticity (93). However, for TLR2, the regulatory role of PI3K
may not involve differential compartmentalization of signaling
complexes (Peres and Madrenas, unpublished observations).
Sustained ligation of TLR2 with TLR1, TLR6, or TLR10 brings
the TIR domains within close proximity, forming the platform
for TIR adaptors, and leads to downstream signaling events.
Availability of intracellular adaptors is another factor that can
accommodate different signaling patterns from TLR2. For anti-
inflammatory responses, we already mentioned that TLR2/6 het-
erodimers can use the MAL adaptor molecule leading to PI3K-Akt
activation, which includes IL-10 production among its functional
correlates (93). As previously mentioned, certain macrophage
populations have been shown to induce IFN-β through a TLR2
and TRIF-dependent mechanism (38). Type I IFN have been sug-
gested as initiators of the IL-10 response, but it is not clear if
there is a mechanistic link. However, PBMCs stimulated with heat
killed S. aureus may not require type I IFN for the IL-10 response
(Peres and Madrenas, unpublished observations). Another adapter
linked to TLR-induced PI3K activation is the B-cell adapter for
PI3K (BCAP). It has been shown that the TIR domain of BCAP
interacts with MyD88 and MAL to suppress production of pro-
inflammatory cytokines in bone-marrow-derived macrophages
(94, 95) (Figure 2). Mice deficient in BCAP showed impaired Akt
phosphorylation in response to stimulation with LPS, CpG, and
Pam3CSK4 (94), but the phosphorylation of the MAP kinases
extracellular-signal regulated kinase (ERK) and JNK in response
to LPS was not affected (95).
Interestingly, Ni et al. (95) found that IL-10 production after
LPS stimulation did not differ between the BCAP-deficient and
control groups, seemingly contradicting the findings in p110δ
enzymatically deficient mice (2). Further investigation is required
on the possible differential role of PI3K in TLR4- and TLR2-
mediated anti-inflammatory responses. Since PI3K constitutes a
relatively large family of enzymes comprising three classes, each
with several isoforms that serve diverse cellular functions, one
cannot rule out that the plasticity in TLR signaling results, in part,
from different usage of these isoforms. Use of chemical inhibi-
tion of the PI3K/Akt pathway has its limitations. For example,
the often-used wortmannin is a broad PI3K inhibitor that may
impact other cellular functions. Therefore, further investigation
is required to determine the mechanistic role of different PI3K
isoforms in the TLR2-dependent anti-inflammatory response.
Toll-like receptor 2 signaling plasticity can also result from the
specific stage of differentiation of the cell expressing this recep-
tor. The main cell candidate responsible for the IL-10 response
in human PBMCs is the CD14+ monocyte. Experiments using
in vitro differentiation of primary monocytes into macrophages
and DCs indicate that macrophages, not DCs are the pri-
mary mediators of the immunomodulatory or anti-inflammatory
response (71). Recently, a potential mechanism has been hypoth-
esized that could explain this difference in TLR2-dependent IL-10
secretion. DC-SCRIPT is a transcription factor found in all DC
subsets, including in vitro monocyte-derived DCs, myeloid DCs,
plasmacytoid DCs, and Langerhans cells, but is not expressed
in other leukocytes (96). When DC-SCRIPT was knocked down
using siRNA, the IL-10 levels were increased compared to con-
trols in response to stimulation with LPS and R848, a TLR7/8
ligand (97). In contrast, the IL-10 response to poly I:C was
unchanged (98). Unfortunately, TLR2 ligands were not exam-
ined in this study. DC-SCRIPT is a negative regulator of IL-10
production following activation of certain TLRs and represents
a plausible explanation for the differences observed between
monocyte-derived macrophages and DCs. Further investigation
is required to characterize anti-inflammatory TLR2 responses in
both monocyte-derived DCs and in vivo DC populations.
Considering all the factors mentioned above, we propose that
the plasticity of TLR2 signaling is a reflection of the evolving
nature of the bacterial cell wall. As a result of the selective pres-
sure exerted on the microbes by the interacting hosts, the array
of ligands for TLR2 increases. The versatility accumulated by the
immune system over the phylogeny of the species is thus revealed
by the interaction with these ligands. The outcome of these inter-
actions may involve and, indeed, favor the microbial capacity to
induce anti-inflammatory responses not only as an immune eva-
sion mechanism, which ultimately may eliminate the host and
negatively impact the microbe, but also as a way to promote
pathobiosis or even commensalism.
THERAPEUTIC POTENTIAL OF TLR2 SIGNALING PLASTICITY
The evolving nature of MAMPs upon host-imposed selective
pressure offers opportunities to explore novel immune modula-
tory mechanisms with therapeutic potential. The importance of
TLR-induced anti-inflammatory pathways has been corroborated
in vivo. For example, chronic recurrent multifocal osteomyelitis
(CRMO) is an autoimmune bone disorder, and patients were
Frontiers in Immunology | Microbial Immunology October 2013 | Volume 4 | Article 347 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Li et al. Plasticity of TLR2 signaling
TLR2/1 or TLR2/6 TLR2/10TLR2/2
TLR2/1 Ligands
PAM3CSK4
Triacylated Lipopeptides
??
TLR2/6 Ligands
PAM2CSK4
Diacylated Lipopeptides
LTA
MALP2
??
?? ??
?? ??
M
y
D
8
8
M
y
D
8
8M
A
L
M
A
L
Nucleus
TLR2 Ligands
Zymosan
Lipoarabinomannan
Etc.
PI3KBCAP
     ?
MAPKs
NF-κB 
Akt
MAPKs
mTOR
NF-κB
Proin"ammatory 
Pathway 
Anti-in"ammatory 
Pathway
DC-SCRIPT
Proin"ammatory Cytokines
IL-1β, IL-6, IL-12p40, TNFα
Anti-in"ammatory Cytokines
IL-10
T
R
IF
T
R
IF
Endosome
IRF3
IRF7
Type I Interferons
 IFN-β, IFN-α4
TLR2/?
FIGURE 2 | Model for pro- and anti-inflammatory signaling throughTLR2.
Like TLR4, pro-inflammatory signaling through TLR2 involves the recruitment
of the adaptors MyD88 and MAL/TIRAP to induce inflammatory cytokines
through ERK, JNK, and NF-κB. BCAP interacts with both MyD88 and MAL to
recruit PI3K, which then phosphorylates Akt, inducing the secretion of
anti-inflammatory IL-10. The involvement of DC-SCRIPT in suppressing
TLR2-depdendent IL-10 production has not been tested. TLR2 activation can
also induce type I interferons through IRF3 and IRF7 from endosomal
compartments (38, 92). Differences in signaling between the TLR2/1 and
TLR2/6 heterodimers, as well the potential involvement of hypothesized
TLR2/2 and TLR2/10 receptor conformations presents another challenge in
understanding the plasticity of TLR2-dependent responses.
shown to have impaired IL-10 expression downstream of TLR4
(99). Hofmann et al. (99) showed that CRMO patients have defi-
cient ERK 1 and 2 signaling following TLR4 activation. This
results in an increase in the TNFα/IL-10 ratio, providing a possi-
ble mechanism for the pathogenesis of CRMO and suggests novel
therapeutic targets. TLR2-dependent anti-inflammatory signaling
may prove to be equally important in other clinical settings.
The lipopeptides that can act on TLR2 have garnered much
attention as tools to understand the immune system and also as
potential adjuvants because of the feasibility of their synthesis in
the laboratory setting. Much of our understanding of TLR2 signal-
ing comes from the use of the synthetic lipopeptides, Pam3CSK4,
and Pam2CSK4, but it is unknown to what extent these lig-
ands recapitulate the binding of and responses to physiological
ligands. Pam3CSK4 and Pam2CSK4 were used to structurally
characterize the binding of TLR2/1 and TLR2/6 to their cognate
ligands (66, 67). Using x-ray crystallography, the binding profiles
of human TLR2 were identified. TLR2 recognizes two acyl moi-
eties on Pam2CSK4 or Pam3CSK4 while TLR1 recognizes one
acyl moiety, and TLR6 does not have a binding pocket for any
acyl chains. It is interesting to note that the accessory molecule
CD14 has been reported to bind Pam3CSK4 and other triacy-
lated lipopeptides and induce the formation of TLR2/1 signaling
complexes (87). Presently, this finding has not been reported with
Pam2CSK4. In addition, LPS binding protein (LBP) appears to
play an independent and redundant role in Pam3CSK4 or bac-
terial lipoprotein presentation to the TLR2 signaling complex
(100). Intriguingly, Pam2CSK4 signaled independently of TLR6
in murine bone marrow-derived macrophages and B lymphocytes
(69). Currently, there is still no single defined natural ligand for
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TLR2. Furthermore, the differences in PRR signaling between mice
and humans as well as ambiguities in potential ligands have yet to
be elucidated. For now, it is believed that bacterial lipoproteins are
the family of biomolecules responsible for TLR2 signaling (64).
Synthetic lipopeptides have also been examined as adjuvants
(101). Pam3CSK4 showed promise for live-attenuated vaccines
as it enhanced infection of paramyxoviruses in vitro and in vivo
(102) as well as RSV infection in multiple cell types. However, the
related lipopeptides Pam-Cys-SK4 and PHCSK4 did not activate
TLR signaling although they were able to enhance the binding
and infection of APCs by the virus, even though RSV primarily
targets airway epithelial cells (103). The enhanced infectivity may
allow live-attenuated vaccines to produce a more robust immune
response and confer significantly stronger secondary responses
(102, 103). In this regard, Pam-Cys-SK4 and PHCSK4 could be
useful in the development of vaccines.
Synthetic lipopeptides targeting TLR2 have also been consid-
ered as potential modulators of T cell subset differentiation, which
may be a strategy to confer protection to certain chronic inflam-
matory, immune mediated diseases or to enhance vaccine efficacy
(104). For example, Pam3CSK4 enhanced CD8+ regulatory T cell
(Treg) survival (105). Interestingly, glycolipopeptide constructs
can be used to design composite tumor vaccines (106). These
compounds contain carbohydrate antigens, CD4+ or CD8+ T
cell epitopes, and TLR2 stimulating lipid chains. By compound-
ing these properties, improved vaccines against malignant cancer
cells may be generated. Also, by introducing structural modifi-
cations in native ligands it should be possible to enhance the
anti-inflammatory properties of TLR2 signaling (107).
Finally, a role for TLRs (specifically TLR2) and other PRRs is
emerging in the crosstalk between the host and its microbiome.
TLR2 has been linked to the establishment and regulation of the
microbiota in different sites. One such site is the skin, where
staphylococcal LTA has been shown to down-regulate inflam-
matory cytokine release by keratinocytes in a TLR2-dependent
manner (5). Another site is the gut, where microbiota has been
shown to play an active role in the maturation and homeostasis
of the host immune system (108, 109). Studies conducted on Bac-
teroides fragilis, a ubiquitous gut microbe, revealed that polysac-
charide A (PSA) was involved in correcting CD4+ T cell deficiency
and the TH1/TH2 imbalance in germ-free mice (109). The signifi-
cance of this mechanism has been demonstrated in disease models,
where experimental colitis induced by Helicobacter hepaticus was
more severe in B. fragilis ∆PSA compared to wild-type B. fragilis.
Moreover, purified PSA protects animals from experimental colitis
through an IL-10 dependent mechanism (110). PSA was found to
signal through TLR2 directly on Treg cells to promote immune
tolerance by suppressing TH17 responses (6). It has been sug-
gested that PSA is a member of a new class of TLR ligands known
as symbiont-associated molecular patterns (SAMPs) where TLR
signaling paradoxically may allow persistent colonization. These
effects may not be limited to B. fragilis but be shared by other
components of the microbiome (e.g., clostridia) (111, 112).
The immunological environment in the gut and other sites
where the host interacts with its microbiome is a critical site for
host-microbe co-evolution and dynamic selection of MAMPs and
PRRs. There is an advantage for the host to evolve sophisticated
mechanisms to differentially respond to molecular patterns associ-
ated with symbiosis or pathogenicity. The involvement of TLR2 in
regulating the gut microbiota and preventing dysbiosis may be just
one example of the complexity of TLR ligand co-evolution, pro-
viding additional impetus for further investigation of the plasticity
of TLR2 signaling and potential avenues to exploit it.
CONCLUSION
While the pro-inflammatory responses activated upon detection of
Gram-negative and Gram-positive bacteria by TLRs have been well
characterized, the TLR-triggered anti-inflammatory responses are
only beginning to be elucidated. The current literature regard-
ing these new responses focus on TLR4 but TLR2 is especially
interesting to study in this context given the diversity in recep-
tor complexes and the crosstalk between downstream signaling
cascades. The challenges ahead are not trivial: (i) the array of lig-
ands for TLR2 may be larger than originally suspected, and its
characterization may be an ongoing exercise as suggested by the
evidence supporting their evolving nature; (ii) the relevance of
various TLR2 ligands in the context of infection is not clear; and
(iii) the tools used to study TLR2 activation both structurally and
functionally are limited and may not recapitulate the full range of
responses following TLR2 activation in vivo in response to bacte-
ria. However, the therapeutic promise shown by synthetic TLR2
ligands as well as the emerging significance of TLR2 in regulating
the gut microbiota, among other reasons, justify further investiga-
tion into the plasticity of TLR2-mediated MAMP recognition and
downstream signaling.
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